A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage

Pharmaceutical Research

Volumn 18, Issue 6, 2001, Pages 846-851

  Lee, C C ^a   Huang, T S ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

DNA damage; GL331; Telomere; Topoisomerase II; VP 16

Indexed keywords

4' NOR 4BETA (4'' NITROANILINO) 4 DESOXYPODOPHYLLOTOXIN; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); PODOPHYLLOTOXIN DERIVATIVE; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; DNA CLEAVAGE; DNA DAMAGE; ENZYME ACTIVITY; GENE SEQUENCE; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STOMACH ADENOCARCINOMA; TELOMERE; TOXIN ANALYSIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; HUMANS; INTERCALATING AGENTS; TELOMERASE; TELOMERE; TUMOR CELLS, CULTURED;

EID: 0034858972     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011048831698     Document Type: Article

References (28)

1. Clinical experience with intravenous podophyllotoxin
2. DNA topoisomerases in cancer therapy
3. DNA topoisomerase poisons as antitumor drugs
4. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
5. Non-intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
6. A consensus sequence for cleavage by vertebrate DNA topoisomerase II
7. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin
8. Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats
9. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by a ellipticine derivative
10. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide
11. Analysis of eukaryotic topoisomerase II cleavage site in the presence of the quinolone CP-115,953 reveals drug-dependent and independent recognition elements
12. DNA topoisomerase II cleavage of telomeres in vitro and in vivo
13. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments
14. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding
15. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening
16. New trials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors
17. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL 331, a new homolog of etoposide
18. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP- 16 in killing refractory cancer cells
19. In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents
20. Effect of 4β-arylamino derivatives of 4′-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants
21. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity
22. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors
23. Telomere length regulation
24. DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells
25. On the mechanism of interaction od DNA topoisomerase II with chemotherapeutic agents
26. Antitumor agents 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4′-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II
27. Antitumor agents. 113. New 4β-arylamino derivatives of 4′-O-demethylepipodophyllotoxic and related compounds as potent inhibitors of human DNA topoisomerase II
28. Antitumor agents, 130. Novel 4β-arylamino derivatives of 3′,4′-didemethoxy-3′4′-dioxo-4-deoxypodophyllotoxin as potent inhibitors of human DNA topoisomerase II